Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia

Brief summary

The goal of this clinical trial is to learn if nebulized colistimethate sodium can prevent pneumonia in ventilated children. The main question it aims to answer is: • Does nebulized colistimethate sodium lower the number of times participants develop ventilation associated pneumonia? Researchers will compare nebulized colistimethate sodium to a placebo (a look-alike substance that contains no drug) to see if nebulized colistin works to prevent ventilation associated pneumonia in children. Participants will: * Take nebulized colistimethate sodium or a placebo twice a day for a maximum of 5 days. * Will be followed to check for pneumonia occurrence while they are on mechanical ventilation.

Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.

Trial details

acronym

ColiPed

status

NOT_YET_RECRUITING

phase

PHASE2, PHASE3

study type

INTERVENTIONAL

enrollment

400

sponsor

University Hospital Fattouma Bourguiba

conditions

Ventilator Associated Pneumonia

interventions

DRUG: colistimethate sodium; DRUG: 0.9% Saline

start date

2027-01-01

start date type

ESTIMATED

primary completion date

2028-12-31

has results

false

data source

ClinicalTrials.gov

data processed

2026-10-29T09:00:05

modifications

selected fields only; whitespace normalized; brief summary truncated to 2,000 characters